Serum presepsin levels in patients with decompensated heart failure

    Authors

    Keywords

    decompansated heart failure, presepsin, inflammation

    DOI

    https://doi.org/10.15836/ccar2016.525

    Full Text

    **Background:** Acute decompensated heart failure (HF) represents a major public health burden, and it is understood that HF is not simply a mechanical failure of the heart pump but inflammatory mediators play a crucial role in the development of HF. Possible targets involve pro- and anti-inflammatory cytokines and their receptors, endotoxins, adhesion molecules, nitric oxide and nitric oxide synthase, reactive oxygen species, and different types of leucocytes. Recently, the soluble CD14 subtype; presepsin (PSP) has been suggested as a reliable marker for systemic inflammation which have not been studied in DHF setting. Our aim of this study was to evaluate serum PSP levels in patients who were admitted to coronary care unit with DHF. **Patients and Methods:** 50 patients with confirmed acute decompensated HF (27 male – 54%; 23 female – 46%) and 51 controls without (20 DHF – 39.2% male; 31 female – 60.8%) were included in our study. Besides routine clinical and laboratory data, brain natriuretic peptide (BNP) and PSP levels were measured in peripheral venous blood samples of all the participants. **Results:** PSP levels were significantly higher in patients with HF than controls (1107.98±1001.15 vs 540.47±526.9 pg/ml, p=0.001). Cut-off value for PSP was 442 pg/ml to detect HF with 76%, sensitivity, 62.7% specificity, 66.7% positive predictive value and 72.7% negative predictive value (CI: 0,975-1,000). The HF diagnostic accuracy of PSP was not superior to that of BNP (AUC: 0.99 vs 0.74). **Conclusions:** PSP levels are significantly elevated in patients with HF compared to controls. PSP may be a new marker for HF.

    Cardiologia Croatica
    Back to search

    Serum presepsin levels in patients with decompensated heart failure

    Extended Abstract
    Issue10-11
    Published
    Pages525
    PDF via DOIhttps://doi.org/10.15836/ccar2016.525
    decompansated heart failure
    presepsin
    inflammation

    Authors

    Fatma Nihan Turhan CaglarORCIDBakirkoy Dr. Sadi Konuk Education and Research Hospital, Cardiology Department, Istanbul, Turkey
    Nilgün IsiksacanORCIDBakirkoy Dr. Sadi Konuk Education and Research Hospital, Biochemistry Department, Istanbul, Turkey
    Ismail BiyikDepartment of Cardiology, Usak State Hospital, Usak, Turkey
    Hakan SahinBakirkoy Dr. Sadi Konuk Education and Research Hospital, Cardiology Department, Istanbul, Turkey
    Dilay KarakozakBakirkoy Dr. Sadi Konuk Education and Research Hospital, Cardiology Department, Istanbul, Turkey
    Fahrettin KatkatBagcilar Education and Research Hospital, Cardiology Department, Istanbul, Turkey
    Faruk AkturkBakirkoy Dr. Sadi Konuk Education and Research Hospital, Cardiology Department, Istanbul, Turkey
    Nursel Kocamaz*Department of İnternal Medicine, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey

    *Correspondence email: nisiksacan@gmail.com

    Full Text

    Background: Acute decompensated heart failure (HF) represents a major public health burden, and it is understood that HF is not simply a mechanical failure of the heart pump but inflammatory mediators play a crucial role in the development of HF. Possible targets involve pro- and anti-inflammatory cytokines and their receptors, endotoxins, adhesion molecules, nitric oxide and nitric oxide synthase, reactive oxygen species, and different types of leucocytes. Recently, the soluble CD14 subtype; presepsin (PSP) has been suggested as a reliable marker for systemic inflammation which have not been studied in DHF setting. Our aim of this study was to evaluate serum PSP levels in patients who were admitted to coronary care unit with DHF.

    Patients and Methods: 50 patients with confirmed acute decompensated HF (27 male – 54%; 23 female – 46%) and 51 controls without (20 DHF – 39.2% male; 31 female – 60.8%) were included in our study. Besides routine clinical and laboratory data, brain natriuretic peptide (BNP) and PSP levels were measured in peripheral venous blood samples of all the participants.

    Results: PSP levels were significantly higher in patients with HF than controls (1107.98±1001.15 vs 540.47±526.9 pg/ml, p=0.001). Cut-off value for PSP was 442 pg/ml to detect HF with 76%, sensitivity, 62.7% specificity, 66.7% positive predictive value and 72.7% negative predictive value (CI: 0,975-1,000). The HF diagnostic accuracy of PSP was not superior to that of BNP (AUC: 0.99 vs 0.74).

    Conclusions: PSP levels are significantly elevated in patients with HF compared to controls. PSP may be a new marker for HF.